电子烟或雾化相关肺损伤的临床表现、治疗与短期结局:一项前瞻性观察性队列研究
这项多中心前瞻性观察性队列研究纳入2019年6月27日至10月4日在美国犹他州Intermountain Healthcare系统内就诊的60例电子烟或雾化相关肺损伤患者,其中33例(55%)入住ICU。常见症状为全身症状(88%)、呼吸道症状(98%)和胃肠道症状(90%);54例(90%)接受抗生素,57例(95%)接受激素。2周内6例(10%)再入院,其中3例(50%)复发使用电子烟或雾化产品;26例随访中影像和肺功能虽改善但多有残留异常;2例死亡,肺损伤被认为是促死因素而非死因。作者认为该病为临床诊断,需高度怀疑。
要点
- 60例电子烟或雾化相关肺损伤患者中33例(55%)入住ICU,提示该病可致严重肺损伤。
- 临床表现以呼吸道症状(98%)、胃肠道症状(90%)和全身症状(88%)为主,易与感染性肺病重叠。
- 治疗中54例(90%)使用抗生素、57例(95%)使用激素,但原文未给出具体剂量和疗程。
- 2周内6例(10%)再入院,其中3例(50%)复发使用电子烟或雾化产品。
- 短期随访中影像和肺功能虽改善,但67%(10/15)胸片和67%(6/9)肺功能仍有残留异常。
适用人群与场景
- 2019年6月27日至10月4日在美国犹他州Intermountain Healthcare系统内就诊的所有电子烟或雾化相关肺损伤患者,共60例,来自13家医院或门诊诊所。
- 33例(55%)入住ICU。
处置流程与药物剂量
- 原文提及系统内传播了拟议的诊断和治疗指南,但未给出具体推荐条款。
- 54例(90%)给予抗生素,57例(95%)给予激素;原文未报告具体药物、剂量、途径、频次或疗程。
研究设计与关键结果
- 多中心前瞻性观察性队列研究,纳入60例患者,来自13家医院或门诊诊所;33例(55%)入住ICU。
- 症状:53例(88%)有全身症状,59例(98%)有呼吸道症状,54例(90%)有胃肠道症状。
- 治疗:54例(90%)使用抗生素,57例(95%)使用激素。
- 2周内6例(10%)再入住ICU或医院,其中3例(50%)复发使用电子烟或雾化产品。
- 26例在2周内随访,临床和影像均改善,但10/15(67%)胸片和6/9(67%)肺功能仍有残留异常。
- 2例死亡,肺损伤被认为是促死因素而非死因。
证据类型、等级与局限
- 证据类型:多中心前瞻性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,电子烟或雾化相关肺损伤是一种新兴疾病,可导致严重肺损伤并伴全身和胃肠道症状,应保持高度怀疑。
- 作者指出,该病仍为临床诊断,症状与感染性及其他肺病重叠;在病因、最佳治疗和长期结局尚未明确前,维持高度怀疑很重要。
- 原文未据此给出具体推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: An ongoing outbreak of lung injury associated with e-cigarettes or vaping (also known as E-VALI or VALI) started in March, 2019, in the USA. The cause, diagnosis, treatment, and course of this disease remains unknown.
METHODS: In this multicentre, prospective, observational, cohort study, we collected data on all patients with lung injury associated with e-cigarettes or vaping seen in Intermountain Healthcare, an integrated health system based in Utah, USA, between June 27 and Oct 4, 2019. Telecritical care, based in Salt Lake City, UT, USA, was used as the central repository for case validation, public reporting, and system-wide dissemination of expertise, which included a proposed diagnosis and treatment guideline for lung injury associated with e-cigarettes or vaping. We extracted data on patient presentation, treatment, and short-term follow-up (2 weeks after discharge) from chart review and interviews with patients undertaken by the Utah Department of Health (Salt Lake City, UT, USA).
FINDINGS: 60 patients presented with lung injury associated with e-cigarettes or vaping at 13 hospitals or outpatient clinics in the integrated health system. 33 (55%) of 60 were admitted to an intensive care unit (ICU). 53 (88%) of 60 patients presented with constitutional symptoms, 59 (98%) with respiratory symptoms, and 54 (90%) with gastrointestinal symptoms. 54 (90%) of 60 were given antibiotics and 57 (95%) were given steroids. Six (10%) of 60 patients were readmitted to an ICU or hospital within 2 weeks, three (50%) of whom had relapsed with vaping or e-cigarette use. Of 26 patients who were followed up within 2 weeks, despite clinical and radiographic improvement in all, many had residual abnormalities on chest radiographs (ten [67%] of 15) and pulmonary function tests (six [67%] of nine). Two patients died and lung injury associated with e-cigarettes or vaping was thought to be a contributing factor, but not the cause of death, for both.
INTERPRETATION: Lung injury associated with e-cigarettes or vaping is an emerging illness associated with severe lung injury and constitutional and gastrointestinal symptoms. Increased awareness has led to identification of a broad spectrum of severity of illness in patients who were treated with antibiotics and steroids. Despite improvement, at short-term follow-up many patients had residual abnormalities. Lung injury associated with e-cigarettes or vaping remains a clinical diagnosis with symptoms that overlap infectious and other lung diseases. Maintaining a high index of suspicion for this disease is important as work continues in understanding the cause or causes, optimal therapy, and long-term outcomes of these patients.
FUNDING: Intermountain Healthcare.
参考来源
- Blagev DP, Harris D, Dunn AC, et al. Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping: a prospective observational cohort study. Lancet. 2019. PMID: 31711629. doi:10.1016/S0140-6736(19)32679-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。